Area of research
Molecular Biology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Medicine, Internal medicine, Capecitabine, Epirubicin, Nausea, and Placebo.
Efficient and multiplexed somatic genome editing with Cas12a mice
CD1d protects against hepatocyte apoptosis in non-alcoholic steatohepatitis
A cohort autopsy study defines COVID-19 systemic pathogenesis
Sulforaphane activates anti-inflammatory microglia, modulating stress resilience associated with BDNF transcription
Early extubation followed by immediate noninvasive ventilation vs. standard extubation in hypoxemic patients: a randomized clinical trial
Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial
Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer.
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study
Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type <i>KRAS</i> Metastatic Colorectal Cancer